Talbot Financial LLC Purchases 5,839 Shares of Amgen Inc. $AMGN

Talbot Financial LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 11.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 58,661 shares of the medical research company’s stock after buying an additional 5,839 shares during the quarter. Talbot Financial LLC’s holdings in Amgen were worth $16,554,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. OLD National Bancorp IN lifted its position in Amgen by 296.2% in the 2nd quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock valued at $5,027,000 after acquiring an additional 13,460 shares in the last quarter. Atlantic Union Bankshares Corp raised its stake in shares of Amgen by 165.0% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after purchasing an additional 6,627 shares during the period. Trinity Legacy Partners LLC raised its stake in shares of Amgen by 3.9% in the 1st quarter. Trinity Legacy Partners LLC now owns 16,132 shares of the medical research company’s stock valued at $5,026,000 after purchasing an additional 612 shares during the period. L2 Asset Management LLC lifted its holdings in shares of Amgen by 50.8% in the second quarter. L2 Asset Management LLC now owns 9,837 shares of the medical research company’s stock valued at $2,747,000 after purchasing an additional 3,314 shares in the last quarter. Finally, Stephens Inc. AR boosted its position in shares of Amgen by 14.2% during the second quarter. Stephens Inc. AR now owns 95,731 shares of the medical research company’s stock worth $26,729,000 after buying an additional 11,888 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

NASDAQ:AMGN opened at $324.42 on Friday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.38. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The firm has a fifty day simple moving average of $318.58 and a 200 day simple moving average of $299.86. The stock has a market capitalization of $174.69 billion, a PE ratio of 25.07, a P/E/G ratio of 2.95 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period in the prior year, the firm posted $5.58 earnings per share. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen’s dividend payout ratio (DPR) is 73.57%.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald lifted their target price on Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Piper Sandler lifted their price objective on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research report on Tuesday, November 11th. DZ Bank raised their target price on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Finally, HSBC reiterated a “buy” rating and issued a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $332.85.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.